What Are the Main Side Effects of Using Metformin for Hair Regrowth?

Metformin, a medication commonly prescribed to treat type 2 diabetes, has been tested in laboratory and animal studies and a few small case reports as a possible hair-loss treatment. While research into this use is at an early stage, it’s essential to understand that metformin is not officially approved by the U.S. Food and Drug Administration (FDA) for hair loss treatment. Its use for this purpose is considered off-label, meaning that any benefits—and side effects—must be evaluated with particular caution.

Why Metformin Is Being Studied for Hair Loss

Metformin works by improving insulin sensitivity and lowering blood sugar levels. However, scientists have discovered that it also influences a molecule called AMP-activated protein kinase (AMPK), which plays a role in cell energy balance. When AMPK is activated, it can improve how cells grow and divide. Because hair follicles are made up of rapidly dividing cells, this effect has prompted research into whether metformin could help reverse hair thinning or stimulate regrowth.

Laboratory and mouse studies have tested metformin on hair follicles. One study found that metformin increased the hair-forming activity of mouse skin-cell aggregates grafted onto mice (Sun et al., 2022). Another tested a topical metformin nanoparticle system in a mouse model of androgenetic alopecia (Mai et al., 2025). These are laboratory and animal studies; they do not show that metformin regrows hair in people.

Understanding the Side Effects: What Happens Inside the Body

When used orally (as a tablet), metformin’s side effects are well-documented through decades of use in diabetes management. The most common include gastrointestinal disturbances—nausea, diarrhea, stomach cramps, and loss of appetite. These occur because metformin alters how the intestines absorb glucose and how the liver produces it.

In hair regrowth contexts, some researchers are exploring topical metformin (applied to the scalp). While this might reduce systemic exposure, the data on its safety profile through the skin are still extremely limited. It’s important to differentiate between systemic effects (those that affect the whole body) and local effects (those limited to the scalp or skin). No human trials have yet been published showing the long-term skin or follicular safety of topical metformin.

Gastrointestinal Effects: Still the Most Common Concern

According to the FDA’s official prescribing information for metformin (FDA, 2024), the most frequently reported side effects are gastrointestinal. In the placebo-controlled trial in the US label, diarrhea occurred in 53% of people on metformin versus 12% on placebo, and nausea or vomiting in 26% versus 8%. Diarrhea led 6% of people to stop metformin (metformin label, DailyMed). However, if metformin is absorbed through the scalp—even in small amounts—similar reactions could theoretically occur in sensitive individuals.

Lactic Acidosis: A Rare but Serious Risk

The most serious potential side effect of metformin is lactic acidosis, a buildup of lactic acid in the blood. The US label carries a boxed warning for it: postmarketing cases have resulted in death. It is rare. A 2003 analysis of 194 trials and cohort studies found no cases in about 37,000 patient-years of metformin use and put the likely upper limit at 8.1 cases per 100,000 patient-years (Salpeter et al., 2003); the authors note this applies to metformin prescribed under study conditions, with its contraindications respected. The risk rises when kidney function is impaired. The label says kidney function (eGFR) should be checked before starting and during treatment, that metformin must not be used if eGFR is below 30 mL/min/1.73 m², and that it may need to be stopped around iodinated contrast imaging. While this risk is associated primarily with oral use, no research has definitively ruled out the possibility of transdermal (through the skin) absorption leading to similar systemic exposure.

Possible Hormonal and Nutritional Effects

Metformin may lower vitamin B12 levels. Its US label advises measuring vitamin B12 at 2- to 3-year intervals. B12 deficiency can cause fatigue, nerve problems and anemia (NIH Office of Dietary Supplements). Because hair health depends on B vitamins, this side effect could indirectly worsen hair shedding or fragility if left unaddressed.

In addition, metformin may affect androgen balance—the hormones involved in male and female pattern baldness. Metformin is used in polycystic ovary syndrome (PCOS), where insulin resistance can raise androgen levels, but a 2003 trial of metformin for PCOS-related hirsutism found almost no change in androgen levels (Harborne et al., 2003). Whatever the effect, altering hormonal levels without medical supervision could also trigger unexpected effects on hair growth cycles.

Skin Reactions: What’s Known So Far

There are few published data on the skin safety of topical metformin. Human reports are limited to a handful of case reports in scarring alopecia, such as two patients described by Araoye et al. (2020). Home-made or unregulated topical preparations have not been tested for safety.

Research Criticism and Gaps

Despite promising preclinical evidence, the available studies on metformin and hair regrowth are limited in both size and scope. Most have been conducted on animals or cell cultures, with few direct applications to human scalp biology. Furthermore, the animal studies run for short periods, which does not reflect the long-term nature of human hair growth cycles (which can last months).

No completed randomized trial of metformin for hair loss has reported results. Human data are limited to a small uncontrolled case series of oral metformin in scarring alopecia (Bao et al., 2024) and case reports of topical use (Araoye et al., 2020). Therefore, while the science is intriguing, it remains speculative.

The Bottom Line: Metformin’s Hair Potential Comes with Uncertainties

To answer the central question: Yes, metformin can cause side effects when used for hair regrowth, especially when absorbed systemically. The most common risks are gastrointestinal effects and lower vitamin B12 levels, and the label carries a boxed warning for rare but potentially fatal lactic acidosis. A case report also describes hair loss during metformin treatment for PCOS (Journal of Obstetrics and Gynaecology, 2006). For topical use, the risks have not been studied. Metformin is a prescription medicine that is not approved for hair loss; any use for hair is off-label and a decision for a prescribing doctor.

References (APA 7 Format)

• Metformin hydrochloride tablets, US prescribing information (boxed warning: lactic acidosis). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23aa50c5-28fe-4322-b5c6-1f1c48409b16

• Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter, E. E. (2003). Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Archives of Internal Medicine, 163(21), 2594–2602. https://pubmed.ncbi.nlm.nih.gov/14638559/

• National Institutes of Health, Office of Dietary Supplements. Vitamin B12 Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/

• Harborne, L., Fleming, R., Lyall, H., Sattar, N., & Norman, J. (2003). Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 88(9), 4116–4123. https://pubmed.ncbi.nlm.nih.gov/12970273/

• Sun, C., et al. (2022). Metformin promotes the hair-inductive activity of three-dimensional aggregates of epidermal and dermal cells self-assembled in vitro. Skin Pharmacology and Physiology, 35(3), 137–147. https://pubmed.ncbi.nlm.nih.gov/34883492/

• Mai, Q., et al. (2025). Robust metformin nanosystem promotes hair growth in androgenetic alopecia. Research, 8, 0780. https://pubmed.ncbi.nlm.nih.gov/40689361/

• Bao, A., et al. (2024). Low-dose metformin and profibrotic signature in central centrifugal cicatricial alopecia. JAMA Dermatology, 160(11). https://pubmed.ncbi.nlm.nih.gov/39230880/

• Araoye, E. F., Thomas, J. A. L., & Aguh, C. U. (2020). Hair regrowth in 2 patients with recalcitrant central centrifugal cicatricial alopecia after use of topical metformin. JAAD Case Reports, 6(2), 106–108. https://pubmed.ncbi.nlm.nih.gov/32016152/

• Acute alopecia due to metformin treatment for polycystic ovarian syndrome. (2006). Journal of Obstetrics and Gynaecology, 26(6), 584–585. https://pubmed.ncbi.nlm.nih.gov/17000520/